By Patrick Wingrove (Reuters) -Swiss drugmaker Novartis said on Thursday it plans to spend $23 billion to build and expand 10 ...

GLP-1 drugs are blockbuster medications for weight loss and Type 2 diabetes. Now doctors are trying them for lymphedema, swelling that can be caused by cancer treatment.

Major” tariffs on pharmaceutical imports are coming soon, President Donald Trump says, pledging that they’d help bring drug ...

Trump doubled down on plans to soon impose “major” pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.

The pharmaceutical and healthcare sectors were previously viewed as a relative safe haven from the tariff-induced market turmoil. The Health Care Select Sector SPDR exchange-traded fund XLV fell 7.8% ...

Trump on Tuesday said his administration will be announcing a “major” tariff on pharmaceuticals “very shortly.” ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Trump on Tuesday said his administration will be announcing a “major” tariff on pharmaceuticals “very shortly.” ...

A consumer-driven weight loss market could put pharma at greater risk if a recession hits; the continued turmoil at FDA and other HHS agencies magnifies the uncertainty facing the industry; Lilly ...

UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

Across Wall Street, 44 publicly traded companies were upgraded Tuesday to an equivalent rating of "buy" or "neutral." ...